Choose a country

United States Flag United States
United Kingdom Flag United Kingdom
Netherlands Flag Netherlands
Germany Flag Germany
Portugal Flag Portugal
Spain Flag Spain
Spain Flag Australia
Germany Flag Sweden
Brazil Flag Brazil
For ALL other countries, please click here.
Patients & Caregivers Healthcare Providers

The nerve to expect more. The nerve to redefine patient expectations.

The VNS Therapy™ System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications

The nerve to expect more. The nerve to redefine patient expectations.

Addressing the risks of uncontrolled seizures requires a proactive treatment strategy

Children with drug-resistant epilepsy (DRE) who are treated with anti-seizure medications (ASMs) alone could suffer from developmental deterioration that impacts motor and social function

Children with drug-resistant epilepsy (DRE) who are treated with anti-seizure medications (ASMs) alone could suffer from developmental deterioration that impacts motor and social function1

Pediatric patients who did not achieve seizure freedom for 5 continuous years were at a 5.2× greater risk of SUDEP (95% CI 1.4-18.5)

Pediatric patients who did not achieve seizure freedom for 5 continuous years were at a 5.2× greater risk of SUDEP (95% CI 1.4-18.5)2

SUDEP=sudden unexpected death in epilepsy

Poorly controlled seizures have serious cognitive consequences in the developing brain (N=198, P<0.0001)

Poorly controlled seizures have serious cognitive consequences in the developing brain (N=198, P<0.0001)3

Pie chart showing percent of patients with ≥50% reduction in seizure frequency

VNS Therapy™ reduces the frequency, duration, and severity of seizures and improves postictal recovery

In a study of 347 pediatric patients followed up for 24 months5:

 

The nerve to enhance a patient’s quality of life

VNS Therapy™ has shown to offer quality-of-life (QoL) benefits that can help patients overcome the obstacles they face in everyday life.

 

3 out of 4 patients experienced improvements in overall QoL7

VNS Therapy™ may be associated with lower SUDEP rates10

Study with 277,661 person-tears of follow up with 2689 deaths, including 632 of SUDEP, showed that long-term VNS Therapy is associated with lower SUDEP rates

The data suggest that SUDEP risk significantly decreases during long-term follow up of patients with refractory epilepsy treated with VNS Therapy.  This finding might reflect several factors, including the natural, long-term dynamic of SUDEP rate, attrition, and the impact of VNS Therapy.  The role of each of these factors cannot be confirmed due to the limitations of the study.10

SUDEP Rate in years 1-2 of VNS Therapy10  

2.47/1000 person-years 

      

SUDEP Rate in years 3-10 of VNS Therapy10  

1.68/1000 person-years

(rate ratio 0.68; 95% confidence interval [CI] 0.53-0.87; P = 0.002)

The nerve to choose a treatment that won't contribute to CNS adverse effects

VNS Therapy™ has proven to be a safe, well-tolerated adjunctive treatment option that can improve your patients’ seizure control without contributing to anti-seizure medication (ASM) toxicity.  Evidence suggests that adjunctive VNS Therapy may allow some patients to reduce their use of ASM's.

 

VNS Therapy™ has proven safety and is well tolerated

VNS Therapy™ has proven safety and is well tolerated

The most common side effects occur during stimulation and typically diminish over time.11,12 The most common side effect of the surgical procedure is infection.13

Epilepsy (US) – The VNS Therapy System is indicated for use as an adjunctive therapy in reducing thefrequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

Incidence of adverse events following stimulation (>5%) were voice alteration, increased coughing, hoarseness, shortness of breath, sore throat and nausea. Infection is the most common side effect of the procedure.

See important safety information at VNSTherapy.com/safety

VNS Therapy™ has no neurotoxic effects or drug interactions11,13

Access resources to support your practice and patients

Access resources to support your practice and patients

Watch real-life patient testimonials

Watch real-life patient testimonials



References: 1. Otsuki T, Kim HD, Luan G, et al. Brain Dev. 2016;38(5):449-460. 2. Sillanpää M, Shinnar S. N Engl J Med. 2010;363(26):2522-2529. 3. Berg, AT, Zelko FA, Levy, SR, et al. Neurology. 2012;79:1384- 1391. 4. Russo A, Hyslop A, Gentile V, et al. J Child Neurol. 2020;883073820974855. doi:10.1177/0883073820974855. 5. Orosz I, McCormick D, Zamponi N, et al. Epilepsia. 2014;55(10):1576-1584. 6. Lo WB, Chevill B, Philip C, et al. Childs Nerv Syst. 2020;10.1007/s00381-020-04962-3. doi:10.1007/s00381-020-04962-3. 7. Englot DJ, Hassnain KH, Rolston JD, et al. Epilepsy Behav. 2017;66:4-9. 8. Soleman J, Stein M, Knorr C, et al. Epilepsy Behav. 2018;88:139-145. 9. Helmers SL, Duh MS, Guerin A, et al. Eur J Paediatr Neurol. 2012;16(5):449-458. 10. Ryvlin P, So EL, Gordon CM, et al. Epilepsia. 2018;59(3):562-572. 11. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415 418. 12. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735. 13. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX.